Dr. Blobel investigates the fundamental mechanisms involving transcription factors, chromatin regulators, and higher order chromatin. He is gearing his basic science discoveries towards genetic and epigenetic treatment modalities. In addition, Dr. Blobel is interested in mechanism of epigenetic memory.
A surgeon-scientist explores exosome-mediated stem cell engraftment as a means to lessen disease severity and enhance quality of life for children with hemoglobinopathies.
Stefano Rivella, PhD, is developing a novel gene therapy that could help patients living with sickle cell disease and other debilitating red blood disorders.
This week’s stories span discovery (of a potential treatment for rare blood diseases), inspiration (from a mother who transformed grief over her daughter’s terminal disease into a foundation helping other families), and finding practical clinical insight (to distinguish a serious knee condition from a drug-treatable infection with similar symptoms).
Pioneering new approaches to diagnosis, care, and treatment for patients with red blood cell disorders with novel gene therapies and stem-cell-based treatments that aim to reduce symptoms and prolong life.
Research in the Abdulmalik Laboratory focuses on the development of novel therapies for the hemoglobinopathies, with a particular emphasis on developing and validating novel therapeutic agents for sickle cell disease.
The Blobel Lab investigates the fundamental mechanisms involving transcription factors, chromatin regulators, and higher order chromatin, gearing its basic science discoveries toward genetic and epigenetic treatment modalities.
